Fig. 7

novel-circ-930 functions as a miRNA-novel-53 sponge on the antifungal immunity of Ae. Aegypti. A Sequence alignment of miRNA-novel-53 and the predicted binding site in novel-circ-930. B Relative luminescence activity after transfection of different plasmids in the S2 cell line. 53 + 930WT, cells transfected with pAc5.1b-miRNA-novel-53 and psiCHECK2-novel-circ-930-WT plasmids; 53 + 930MT, cells transfected with pAc5.1b-miRNA-novel-53 and psiCHECK2-novel-circ-930-MT plasmids; pAc + 930WT, cells transfected with pAc5.1b empty vector and psiCHECK2-novel-circ-930-WT plasmid; pAc + pSi, cells transfected with pAc5.1b and psiCHECK2 plasmids. Each sample had four replicates. The statistical significance of treatment differences was judged using the Student’s t-test. ns, P > 0.05; **P < 0.01. C Quantitative detection of overexpression of circRNA in Aag2. pAlu, cells transfected with pAlu5.1b empty vector; pAlu-930, cells transfected with pAlu5.1b-novel-circ-930. D Quantitative detection of interference of circRNA in Aag2. si930, cells transfected with siRNA of novel-circ-930; si930-C, cells transfected with negative siRNA of novel-circ-930. The results were obtained in triplicate and presented as mean ± SEM. The Student’s t-test was used to determine the statistically significant differences. **P < 0.01, ***P < 0.001. E Localization of miRNA-novel-53 and novel-circ-930 was performed with FISH in Aag2 cells. Green, novel-circ-930; red, miRNA-novel-53; blue, Hoechst 33342. Scale bar, 10 μm